Loading...
XHKG
1696
Market cap272mUSD
May 30, Last price  
4.56HKD
1D
0.22%
1Q
16.92%
IPO
-48.76%
Name

Sisram Medical Ltd

Chart & Performance

D1W1MN
P/E
10.84
P/S
0.78
EPS
0.05
Div Yield, %
3.46%
Shrs. gr., 5y
1.16%
Rev. gr., 5y
15.01%
Revenues
349m
-2.83%
101,321,000110,406,000118,156,000136,887,000153,919,000173,520,000162,095,000294,294,000354,480,000359,292,000349,112,000
Net income
25m
-20.23%
5,943,0007,814,0008,055,00011,049,00021,831,00020,785,00013,344,00031,245,00040,170,00031,499,00025,126,000
CFO
33m
-24.70%
22,807,00015,847,00016,013,00017,057,00016,236,00021,037,00025,737,00032,377,00022,039,00043,936,00033,083,000
Dividend
Aug 26, 20240.158 HKD/sh

Profile

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio, including hair removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodelling injectables, personal care, aesthetic dentistry, trans epidermal delivery, cellulite treatment, stretch marks, vascular and pigmented lesions, hydradermabrasion, blepharoplasty-non surgical eyelid lift, liposuction, feminine health, and sexual rehabilitation. The company manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT brands. Sisram Medical Ltd was incorporated in 2013 and is headquartered in Caesarea, Israel.
URL
https://sisram-medical.com/
IPO date
Sep 19, 2017
Employees
1,102
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
349,112
-2.83%
359,292
1.36%
354,480
20.45%
Cost of revenue
313,455
317,233
299,036
Unusual Expense (Income)
NOPBT
35,657
42,059
55,444
NOPBT Margin
10.21%
11.71%
15.64%
Operating Taxes
3,775
4,232
4,162
Tax Rate
10.59%
10.06%
7.51%
NOPAT
31,882
37,827
51,282
Net income
25,126
-20.23%
31,499
-21.59%
40,170
28.56%
Dividends
(9,500)
(10,510)
(9,325)
Dividend yield
0.54%
0.43%
0.22%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
9,203
9,138
8,623
Long-term debt
72,403
75,805
68,316
Deferred revenue
592
Other long-term liabilities
12,985
20,183
1,295
Net debt
1,706
8,186
(20,881)
Cash flow
Cash from operating activities
33,083
43,936
22,039
CAPEX
(2,700)
(8,568)
(64,323)
Cash from investing activities
(6,595)
(32,995)
(52,113)
Cash from financing activities
(16,115)
(20,966)
(17,847)
FCF
58,067
993
23,434
Balance
Cash
71,979
70,601
81,414
Long term investments
7,921
6,156
16,406
Excess cash
62,444
58,792
80,096
Stockholders' equity
484,792
174,878
138,312
Invested Capital
478,534
475,598
392,427
ROIC
6.68%
8.72%
14.09%
ROCE
6.59%
7.87%
11.52%
EV
Common stock shares outstanding
468,343
468,343
466,774
Price
3.78
-28.14%
5.26
-41.03%
8.92
-6.01%
Market cap
1,770,337
-28.14%
2,463,485
-40.83%
4,163,627
-3.12%
EV
1,792,806
2,488,885
4,171,718
EBITDA
52,963
56,294
67,846
EV/EBITDA
33.85
44.21
61.49
Interest
2,064
1,972
Interest/NOPBT
4.91%
3.56%